Stem Cell Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Stem Cell Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Stem Cell Transplantation

Mesenchymal stem cell infusion treats therapy-resistant graft-versus-host disease

According to recent research from Sweden, "Mesenchymal stem cells (MSC) have immunomodulatory effects. The aim was to study the effect of MSC infusion on graft-versus-host disease (GVHD)."

"We gave MSC to eight patients with steroid-refractory grades III-IV GVHD and one who had extensive chronic GVHD. The MSC dose was median 1.0 (range 0.7 to 9x10⁶/kg. No acute side-effects occurred after the MSC infusions.

"Six patients were treated once and three patients twice. Two patients received MSC from HLA-identical siblings, six...

• View Other Issues of Stem Cell Week
  
• View Other NewsRx Publications